Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HWK-016 in Advanced Solid Tumors
NCT07470853Phase 1Recruiting
- Sponsor
- Whitehawk Therapeutics, Inc.
- Start
- Mar 2026
- Primary completion
- Feb 2028
- Countries
- 1
01
Overview
Phase 1, open-label trial of HWK-016 in ovarian cancer and endometrial cancer (EC) (8 arms), sponsored by Whitehawk Therapeutics, Inc. Primary endpoints: Maximum Tolerated Dose at 21 days, Maximum Administered Dose at 21 days and 1 more. Started Mar 2026; status: recruiting.
02
Drugs
HWK-016
03
Conditions
ovarian cancerendometrial cancer (EC)
Beyond the preview
Go deeper on NCT07470853.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07470853.